{"name":"NuVasive (Globus Medical)","slug":"nuvasive","ticker":"GMED","exchange":"NYSE","domain":"globusmedical.com","description":"NuVasive, Inc. is a medical devices company based in San Diego, California. Founded in 1997, it primarily develops medical devices and procedures for minimally invasive spine surgery.","hq":"San Diego, CA","founded":0,"employees":"6000","ceo":"Daniel T. Scavilla","sector":"Spine & Musculoskeletal Devices","stockPrice":91.83,"stockChange":1.83,"stockChangePercent":2.03,"marketCap":"$12.4B","metrics":{"revenue":1201942000,"revenueGrowth":25.7,"grossMargin":68.1,"rdSpend":92626000,"netIncome":40407000,"cash":557243008,"dividendYield":0,"peRatio":23.4,"fiscalYear":"FY2022"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Osteocel Plus patent cliff ($100.0M at risk)","drug":"Osteocel Plus","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Biologic - Osteocel Plus","genericName":"Biologic - Osteocel Plus","slug":"biologic-osteocel-plus","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Biologic - Osteocel Plus","genericName":"Biologic - Osteocel Plus","slug":"biologic-osteocel-plus","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[{"date":"2023-02-23","type":"earnings","headline":"Globus Medical Reports Fourth Quarter and Full Year 2022 Financial Results","summary":"Globus Medical reported fourth quarter and full year 2022 financial results, with revenue increasing 14.1% year-over-year to $434.4 million.","drugName":"","sentiment":"positive"},{"date":"2022-09-01","type":"deal","headline":"Globus Medical Announces Agreement to Acquire NuVasive's Spine Business","summary":"Globus Medical announced an agreement to acquire NuVasive's spine business, expanding its portfolio of spine and musculoskeletal solutions.","drugName":"","sentiment":"positive"},{"date":"2022-06-15","type":"regulatory","headline":"Globus Medical Receives FDA 510(k) Clearance for its Osteocel Plus Bone Graft","summary":"Globus Medical received FDA 510(k) clearance for its Osteocel Plus bone graft, a biologic solution for spinal fusion procedures.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxNNVBhMzV2Q00yWk5zekhzSmVsRWx1b0JJc1gyWndUR2NlVWdhTENwdUdZYUpDMnBXZEtBemhnMTVWSW5hWUtqWV9pQ0N1WktNSER4czRlaWpNSWh3NTFSVkV2VFZPUmF2Z0hfWWNJZE5nZFhlNHBWN2pVUXhjY0FQZ0lJTi1sb1dG?oc=5","date":"2025-05-27","type":"pipeline","source":"MassDevice","summary":"Analysts downgrade Globus Medical on fears of ‘foundational cracks’ - MassDevice","headline":"Analysts downgrade Globus Medical on fears of ‘foundational cracks’","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNNjhSSWxUVjI1WHdSNkE3cU0ybFBOYjBNTHJXWjFna2Q2NDJTWF83SFBUMk9sSlVHTFM3Z3lXTXpwSWN5ZnR0ZUNHeUo2VklPcjVYNFBLZnpFZHBpVVhhTmx0dkZlMThibktENFIzTFVORDhlQ2xXeFNCNUtMbU9Cck0xLXhQVWp0alF2SmV3?oc=5","date":"2025-02-16","type":"deal","source":"Seeking Alpha","summary":"Globus Medical: Some Caution After Its Deal For Nevro (NYSE:GMED) - Seeking Alpha","headline":"Globus Medical: Some Caution After Its Deal For Nevro (NYSE:GMED)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxNRlhmdHR4bjR2N3I3a3lZWFhzV0x3bGJQUkdoM3M5d1RwQlZkeWdGRHBxM1RSSE5CLWhTMkVPLUcyVklIWG1ZcDViT3hzcER4SHhRc2R2eWwwUk80Y2tqWW1KRmM4OGJyX3ZXWEwyX0pyd2FjY043VVpYN0dsTF91dUppdjRQMlVLMjE4UnRCMHY?oc=5","date":"2024-01-26","type":"earnings","source":"MassDevice","summary":"Globus Medical lays off 157 at former NuVasive headquarters - MassDevice","headline":"Globus Medical lays off 157 at former NuVasive headquarters","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTFB0M0lxTGlNcWlvWTc2eDVSVEtVaThlenpmemgtQkZORkpmSVhRVmdLc2NNZjBXNTZaWUtJYTdIcThzODF4VHIySTF2c1NIcFJWMW1lY25mY2E3aXIzdnIxMFVjTWhFblE5aUNBTGxvM2hscllhVWc?oc=5","date":"2023-09-01","type":"deal","source":"MassDevice","summary":"Globus Medical, NuVasive complete merger - MassDevice","headline":"Globus Medical, NuVasive complete merger","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxQLVl5UFJ0ZVVmUTVESGdpamRaT1hyUFM1QnBhTGVuWG5jTW9EaFFnSTBYVUU3R25HT0tHOEhOc1J2R1FPeE5fdE1SY1Yzb012VkRUWENRcUhsRGxJS0NBN1NSZ284MEdrTE45anFvbDUzdFo3b0JjeGVJdzdoWnJDVmFRUFVJdw?oc=5","date":"2023-04-28","type":"regulatory","source":"MassDevice","summary":"NuVasive, Globus Medical shareholders approve merger - MassDevice","headline":"NuVasive, Globus Medical shareholders approve merger","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxNNEQwUWhTYm5RRW1XVVFfT3VSdkN2ams0YTBGX3NLNVFfQWFfV1dWbjJBUUhrRXJCUDgwcDdGVjQ4WUItdDVuc0ktYzhONkZ6MWlVYkpIMUJsa0pPTkxORnpvU3pNR0d1S2Qxd0pybWdnUkFHYnJoWjgyS1p1MWRHUWNOTDREU2szSmRxQ0pKQlo?oc=5","date":"2023-04-27","type":"regulatory","source":"Yahoo Finance","summary":"Globus Medical Shareholders Approve Share Issuance for Merger with NuVasive - Yahoo Finance","headline":"Globus Medical Shareholders Approve Share Issuance for Merger with NuVasive","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxPRTZUekdTOHZaa1hkbkpVazFMNHVUcGVtZWJLV2ZNYUdrQXFsUUJJeXRvRlBLZldaQU9GQzlPcElyZ295MDVHNTB5cVphcTNiNF9LQVFIRDNJUDV4c2VQRVJ6WE5iNzJyZUNJUWQwa2VzX1dSNjR4dU9leWFyXzdVbU5qQUZpZm1aN3MyX0JoTlBKMnR5cUE?oc=5","date":"2023-02-12","type":"deal","source":"Seeking Alpha","summary":"Globus Medical: Does The NuVasive Merger Make Sense? (NYSE:GMED) - Seeking Alpha","headline":"Globus Medical: Does The NuVasive Merger Make Sense? (NYSE:GMED)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxQakZrTWJObzhxYldscjZFRDI0R193S084S185eGFVOGZiNThoSm9DX3VUelo4Nkh5ZkIwbXpBWU5mdnMtLVY5OVE4S1d2MjhqeG11TXR5dHVxLTBYbW5OWkxtQkx2UWV2VXBqcW9GRGFmV1NVcFlsN2dOamk4dlFkbTNiaU1jb3ZX?oc=5","date":"2023-02-09","type":"pipeline","source":"MassDevice","summary":"Globus Medical, NuVasive to merge to form global musculoskeletal company - MassDevice","headline":"Globus Medical, NuVasive to merge to form global musculoskeletal company","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE1UZ1R4T3VZS0FJdldRX2tUVktxRk84Qkg5bHRoN3hLZFd2Q0FBdnFndUdWbmlpWXdRenI4Z3ItVzJ6bjZ4ZkN2bGU3ZnF1YlpYUW9teWpmdGREVDBEaDZWR0tDUVR5T2tFSzRBY3EzNjdhNDUw?oc=5","date":"2021-11-16","type":"pipeline","source":"MassDevice","summary":"Globus Medical could be eying NuVasive - MassDevice","headline":"Globus Medical could be eying NuVasive","sentiment":"neutral"}],"patents":[{"drugName":"Osteocel Plus","drugSlug":"osteocel-plus","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":100000000}],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Medtronic","Stryker","Zimmer Biomet"],"therapeuticFocus":["Spine","Musculoskeletal"],"financials":{"source":"sec_edgar","revenue":1201942000,"revenuePeriod":"2022-12-31","revenueHistory":[{"value":1201942000,"period":"2022-12-31"},{"value":1138988000,"period":"2021-12-31"},{"value":1138988000,"period":"2021-12-31"},{"value":1050582000,"period":"2020-12-31"},{"value":1050582000,"period":"2020-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":92626000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":40407000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":2224505000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":91.83,"previousClose":90,"fiftyTwoWeekHigh":101.4,"fiftyTwoWeekLow":51.79,"fiftyTwoWeekRange":"51.79 - 101.4","fiftyDayAverage":88.91,"twoHundredDayAverage":73.74,"beta":1.09,"enterpriseValue":11734971392,"forwardPE":18.5,"priceToBook":2.71,"priceToSales":4.23,"enterpriseToRevenue":3.99,"enterpriseToEbitda":13.38,"pegRatio":0,"ebitda":877110976,"ebitdaMargin":29.8,"freeCashflow":327532128,"operatingCashflow":753446976,"totalDebt":119440000,"debtToEquity":2.6,"currentRatio":4.26,"returnOnAssets":7.1,"returnOnEquity":12.3,"analystRating":"","recommendationKey":"none","numberOfAnalysts":12,"targetMeanPrice":110.08,"targetHighPrice":123,"targetLowPrice":90,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0.7,"institutionHeldPercent":102.5,"sharesOutstanding":135253051,"floatShares":111931367,"sharesShort":3293919,"shortRatio":2.84,"shortPercentOfFloat":2.4,"epsTrailing":3.92,"epsForward":4.96,"revenuePerShare":21.73,"bookValue":33.86,"officers":[{"age":58,"name":"Mr. David C. Paul","title":"Co-Founder & Executive Chairman"},{"age":45,"name":"Mr. Keith W. Pfeil","title":"CEO, President & Director"},{"age":52,"name":"Ms. Kelly G. Huller Esq.","title":"Executive VP, General Counsel & Corporate Secretary"},{"age":39,"name":"Mr. Kyle R. Klin","title":"Senior VP & CFO"},{"age":58,"name":"Mr. Brian J. Kearns","title":"Senior Vice President of Business Development & Investor Relations"}],"industry":"Medical Devices","irWebsite":"","website":"https://www.globusmedical.com","phone":"610 930 1800"}}